
Should pharmaceutical companies be doing more to advocate open access?
Many public funders have mandated open access to their research and support Plan S. Should pharmaceutical companies follow suit?
A central online news resource for professionals involved in the development of medical publications and involved in publication planning and medical writing.
Many public funders have mandated open access to their research and support Plan S. Should pharmaceutical companies follow suit?
A recent blog for The Scholarly Kitchen suggests mergers, acquisitions, and new regulations are increasingly changing the state of scholarly communications.
Missed ISMPP EU 2019? Read our meeting report to get up to speed!
China has pledged its support for Plan S, an initiative striving to make the results of publicly funded research freely available immediately on publication.
While mirror journals have been proposed as an alternative to hybrid journals for open access publishing under Plans S, recent guidance indicates they may not be compliant.
In a recent opinion piece the traditional scientific publishing model is reviewed alongside recent efforts to change it.
Amy Williams provides an update on open access models and the implications for industry-funded research that might arise from “Plan S”.
Learn more about the potential impact of cOAlition S: a commitment to make all European publicly funded research freely available by 2020.
Robert-Jan Smits, a senior European Commission official comments on whether open access for all scientific papers by 2020 is a realistic goal.